Ophthalmology

Prof. Marie-José Tassignon, past chief and chair, Department of Ophthalmology, Antwerp University and University Hospital Antwerp, Belgium, expands on her AAO presentation by providing an overview of her novel technique in performing a risk-free posterior capsulorhexis.

Chris Brittain, MBBS, BSc, MBA, MRCOphth, vice president and global head of ophthalmology product development for Genentech, provides an overview of the company’s podium presentations from the PDS with ranibizumab to faricimab.

Anne L. Coleman, MD, president of the American Academy of Ophthalmology, offers a preview of its virtual 2020 annual meeting.

Manufacturers are stepping up to design products that will help maximize the safety and efficiency of intravitreal injection.

The benefit is robust across a variety of demographics and baseline disease characteristics, according to data.

Dietary macular pigments, which can now be measured directly and accurately, are hugely important in optimizing visual function, especially as we age.

Silicone rubber balloon scleral buckling is a novel alternative to the current extraocular procedures for treating simple rhegmatogenous retinal detachments. Investigators have found that this surgery may be a novel alternative to the current extraocular procedures for simple RRD.

In one of the first studies of the faceup position, researchers found its use after vitrectomy of rhegmatogenous retinal detachment may be beneficial in some patients.

Understanding the per-person cost differences with 3 key management strategies for a better-informed treatment selection

How this method of anesthesia may provide benefits to both the patient and physician

High-quality images can be useful for early diagnosis, prognosis, monitoring

Following trends by geographic variation in practice patterns, perceptions toward opioids, and patient population

To maintain treatment quality and patient and staff safety in the SARS-CoV-2 era, it is important to minimize clinic visits and maximize the use of imaging modalities. In addition, extending treatment intervals with longer-acting agents is key to maximizing safety and patients’ vision outcomes.

Prof. Frank Holz, Chairman of the Department of Ophthalmology at the University of Bonn, Germany, highlights the topics, lectures, symposia and instructional courses that will take place at this year’s virtual EURETINA conference, and gives his insights on the hot topics of the dynamic retina field.

Study offers a real-world scenario of a very specific, but frequent and crucial aspect of the care of patients with diabetes, suggests clinician

Visual acuity outcomes at 6 months’ post-treatment were similar, regardless of the use of anti-VEGF therapy.

Modifier-25 same-day examinations are critical to the successful treatment and overall health and well being of these patients.

Measuring high-quality care cannot be a barrier to providing it, notes John T. Thompson, MD.

Study points to the possible role of addressing preprocedural anxiety

Investigators find that nanoparticles deliver gene therapy successfully in mice, rats

Automated assistance controls tremor, reduces fatigue, and helps avoid inadvertent injury

Agreement would include global rights for investigational treatment, risuteganib, expected to help reverse vision loss due to dry AMD

Evidence-based medicine can lead to personalized care, better results for patients

Ophthalmologists remain in touch with colleagues while maintaining social distancing

This ability would unlock possibilities for repairing tissue damaged by disease

Watchful waiting may prove to be beneficial in complicated cases

Intravitreal gene therapy continues to be well tolerated; shows robust efficacy

Novartis has announced positive topline results from the phase 3 KITE study of brolucizumab 6 mg versus aflibercept for patients with diabetic macular edema.

Though OCTA has become indispensable for managing macular degeneration and diabetic retinopathy, Robert L. Stamper, MD, explains why the technology must become more sophisticated and evolved before it reaches its full potential for glaucoma specialists.

Interim data update from first cohort using suprachoroidal delivery of RGX-314 expected by end of 2020